Hyperbaric Oxygen — Separating Reimbursed Indications from Longevity Marketing

A patient came in last week. Fifty-eight, healthy, she's paid a deposit for forty hyperbaric sessions because she read it lengthens telomeres. What do I even say?

Start with the pressure. Hyperbaric oxygen is defined as breathing pure oxygen at greater than one atmosphere absolute. Most longevity clinics run so-called soft chambers at 1.3 atmospheres, which is below the threshold where the dissolved oxygen physics meaningfully change. The reimbursed indications require 2.0 to 2.4 atmospheres in a hard-shell chamber.

So if her clinic is using an inflatable soft chamber, the dose isn't even what the studies used?

Correct. The telomere study she read — a single Israeli trial, roughly 35 participants, no clinical endpoints, no control for the supervised rest period — was conducted at 2.0 atmospheres. That is mechanistic and preliminary data only. No guideline body has acted on it.

What are the actual approved indications — the ones where I'd refer a patient without hesitation?

Undersea and Hyperbaric Medical Society and CMS both recognize about fourteen. The strongest evidence is for decompression sickness, arterial gas embolism, carbon monoxide poisoning, clostridial myonecrosis, and osteoradionecrosis. Those have prospective data or controlled trials with clinical endpoints.

Osteoradionecrosis I actually see referred. That one feels like real medicine to patients because it's in a hospital setting.

It is real medicine. Post-radiation tissue is chronically hypoxic and hypovascular. At 2.0 to 2.4 atmospheres, dissolved plasma oxygen extends diffusion distance into tissue the erythrocyte can't reach. Randomized trial evidence supports it for mandibular osteoradionecrosis specifically, and it's guideline-recommended.

So that patient has a completely different conversation than my telomere patient.

Entirely. One is guideline-supported treatment; one is a marketed intervention with mechanistic pilot data and no demonstrated clinical benefit. The 40-session longevity course is not approved, not guideline-recommended, and the pressure at most clinics doesn't even replicate the studied dose.

How do I tell her that without dismissing something she's clearly invested in?

Be precise about what we don't know yet. The biology is real — dissolving more oxygen in plasma under pressure does something. What we lack is a randomized trial showing that something translates to a clinical endpoint she cares about. That's a legitimate gap, not quackery, but it means she's paying to be an early adopter.

Any safety concerns I should mention — contraindications?

Untreated pneumothorax is the absolute contraindication. Relative ones include certain chemotherapy agents — bleomycin, doxorubicin — and claustrophobia. Oxygen toxicity seizures are rare at clinical pressures but real. At soft-chamber pressures the risk is negligible, which is also why the benefit is negligible.

What's the one thing you'd want me to walk away with here?

Pressure is the dose. If the chamber doesn't reach 2.0 atmospheres, the intervention is not the intervention that was studied for any indication — established or experimental. Ask the clinic what pressure they run. That single question separates the conversation.